Bristol Myers Takes $470 Million Write-off and Scraps Orva-Cel CAR-T Program

Earlier this week, the U.S. Food and Drug Administration (FDA) approved Bristol Myers Squibb’s Breyanzi (lisocabtagene maraleucel; liso-cel) for adults with relapsed or refractory (r/r) large B-cell lymphoma (LBCL) after two or more lines of systemic therapy. Liso-cel is a CD-19 directed chimeric antigen receptor (CAR) T cell therapy.